Market Cap 366.33B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.52
Forward PE 14.06
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 4,576,200
Avg Vol 7,382,988
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 41%
Beta 0.34
Analysts Strong Sell
Price Target $249.82

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Maxwell_Osgood
Maxwell_Osgood Mar. 27 at 1:50 AM
$ABBV helpful little bounce today...
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 1:11 AM
$SLS $ABBV Again, for the record, there are NO AML CR2 Patients Surviving at 24 months, absent transplant - in any published trial data any where ... this would include EVERY REGAL Eligible Patient, the Youngest and the So Called Healthiest and the MRD - ALL of them - and there is NIL survival at 24 months ... All 128 P3 Patients - 64 Control ARM on BAT - were enrolled 24 months ago. . . and there is NIL Survival even allowing for a small handful of Super Rare Outliers =/+/- 60 EVENTS and we AWAIT 80 ... BAT for Control is AZA +VEN, Aza+VEN Failed 3 Large Phase 3 Trials - including 2 for AML Remission Maintenance. HELLO??? it's not at all complicated.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 12:41 AM
$SLS $ABBV AMONG ALL These BEGGING SHORT LOWLIFE - not 1 Can Answer... -- FIND 1 Trial where AML Cr2 Patients on BAT, are surviving at ALL at 24 months, absent transplant ... GO AHEAD LOWLIFE FIND 1.... ... You won't because YOU SHORT LOWLIFE LIARS CAN'T its been 24 months since enrollment completed 128 Patients - 64 Control Patients and there are Nil Survivors. Except a Rare Outlier =/+/- 60 EVENTS Just from the Control Arm While We Await 80 . . Gps Arm =+/- 19 / 20 ANY DAY NOW
1 · Reply
Guntz
Guntz Mar. 26 at 9:20 PM
$ABBV $215 is the 200ma. Would be amazing if we can test that tomorrow. Maybe wishful thinking but one can hope lol
1 · Reply
Stockman824
Stockman824 Mar. 26 at 8:17 PM
$ABBV $LLY $NVO $VKTX SOMETHING is LEAKING
0 · Reply
Guntz
Guntz Mar. 26 at 8:14 PM
$ABBV Would love for confirmation tomorrow. Hold $210 and clear $212 with conviction
0 · Reply
Theflash88
Theflash88 Mar. 26 at 7:51 PM
0 · Reply
biolover
biolover Mar. 26 at 7:30 PM
$VKTX  CEO is relaxed ( when u listen to) seems happy with emerging Vanquish data. He indicated to Jeffries active partnering dialogue is ongoing. I would not under estimate pressure on $NVO , $ABBV and others to get something competitive with $LLY tirzepatide. Leaked news could be confused of who is acquiring who. ( seen with Merck RVMD ABBV ).
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 7:05 PM
$SLS $ABBV Phase 3 Registrational results are coming, and will give Gps the FDA Green Light to treat 100,000 AML Patients Currently in Remission. XCCo estimated $280K Rev Per Patient in Year 1. $28B Total Addressable Market - right out of the Gate, worth $40B to Big Pharma. This $5 stock will be $50 the Instant the P3 Results are Announced, and climbing. All P3 Patients were enrolled 24 + months ago, Phase 3 Results are Coming, - conceivably could be ANY DAY NOW. The Future is Inevitable.
0 · Reply
AllDayTrends
AllDayTrends Mar. 26 at 7:00 PM
POWER HOUR LARGE CAP TOP STOCKS $NFLX $ABBV $LIN $CVX
0 · Reply
Latest News on ABBV
Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 7 days ago

Buy Or Fear AbbVie Stock At $210?


Best Dividend Kings: March 2026

Mar 19, 2026, 3:27 AM EDT - 7 days ago

Best Dividend Kings: March 2026

ABM ABT ADM ADP AWR BDX BKH


Harbor Health Care ETF Q4 2025 Portfolio Review

Mar 11, 2026, 8:18 AM EDT - 15 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABVX GMAB LLY MASI MEDI MRK RVMD


February Dividends With 4 Raises: 1.6% Up To 14.5%

Mar 3, 2026, 8:14 AM EST - 23 days ago

February Dividends With 4 Raises: 1.6% Up To 14.5%

BMY BTI MA


Best Dividend Aristocrats For March 2026

Feb 27, 2026, 12:21 PM EST - 27 days ago

Best Dividend Aristocrats For March 2026

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 5 weeks ago

AbbVie Declares Quarterly Dividend


AbbVie: Dominating Immunology While Building Oncology Upside

Feb 17, 2026, 1:11 AM EST - 5 weeks ago

AbbVie: Dominating Immunology While Building Oncology Upside


AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 6 weeks ago

AbbVie sues US health agency over Botox price controls


Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 6 weeks ago

Abbvie sues US health agency over Botox


2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 6 weeks ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE


Dividend Kings: No Ideal Buys In February's 57

Feb 10, 2026, 9:45 AM EST - 6 weeks ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO


AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 8:52 AM EST - 7 weeks ago

AbbVie: The Market Is Getting It Wrong


AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 1:20 PM EST - 7 weeks ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript


AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 7 weeks ago

AbbVie Revenue Rises on Immunology Growth


Best Dividend Kings: January 2026

Jan 25, 2026, 10:11 PM EST - 2 months ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH


Maxwell_Osgood
Maxwell_Osgood Mar. 27 at 1:50 AM
$ABBV helpful little bounce today...
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 1:11 AM
$SLS $ABBV Again, for the record, there are NO AML CR2 Patients Surviving at 24 months, absent transplant - in any published trial data any where ... this would include EVERY REGAL Eligible Patient, the Youngest and the So Called Healthiest and the MRD - ALL of them - and there is NIL survival at 24 months ... All 128 P3 Patients - 64 Control ARM on BAT - were enrolled 24 months ago. . . and there is NIL Survival even allowing for a small handful of Super Rare Outliers =/+/- 60 EVENTS and we AWAIT 80 ... BAT for Control is AZA +VEN, Aza+VEN Failed 3 Large Phase 3 Trials - including 2 for AML Remission Maintenance. HELLO??? it's not at all complicated.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 27 at 12:41 AM
$SLS $ABBV AMONG ALL These BEGGING SHORT LOWLIFE - not 1 Can Answer... -- FIND 1 Trial where AML Cr2 Patients on BAT, are surviving at ALL at 24 months, absent transplant ... GO AHEAD LOWLIFE FIND 1.... ... You won't because YOU SHORT LOWLIFE LIARS CAN'T its been 24 months since enrollment completed 128 Patients - 64 Control Patients and there are Nil Survivors. Except a Rare Outlier =/+/- 60 EVENTS Just from the Control Arm While We Await 80 . . Gps Arm =+/- 19 / 20 ANY DAY NOW
1 · Reply
Guntz
Guntz Mar. 26 at 9:20 PM
$ABBV $215 is the 200ma. Would be amazing if we can test that tomorrow. Maybe wishful thinking but one can hope lol
1 · Reply
Stockman824
Stockman824 Mar. 26 at 8:17 PM
$ABBV $LLY $NVO $VKTX SOMETHING is LEAKING
0 · Reply
Guntz
Guntz Mar. 26 at 8:14 PM
$ABBV Would love for confirmation tomorrow. Hold $210 and clear $212 with conviction
0 · Reply
Theflash88
Theflash88 Mar. 26 at 7:51 PM
0 · Reply
biolover
biolover Mar. 26 at 7:30 PM
$VKTX  CEO is relaxed ( when u listen to) seems happy with emerging Vanquish data. He indicated to Jeffries active partnering dialogue is ongoing. I would not under estimate pressure on $NVO , $ABBV and others to get something competitive with $LLY tirzepatide. Leaked news could be confused of who is acquiring who. ( seen with Merck RVMD ABBV ).
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 7:05 PM
$SLS $ABBV Phase 3 Registrational results are coming, and will give Gps the FDA Green Light to treat 100,000 AML Patients Currently in Remission. XCCo estimated $280K Rev Per Patient in Year 1. $28B Total Addressable Market - right out of the Gate, worth $40B to Big Pharma. This $5 stock will be $50 the Instant the P3 Results are Announced, and climbing. All P3 Patients were enrolled 24 + months ago, Phase 3 Results are Coming, - conceivably could be ANY DAY NOW. The Future is Inevitable.
0 · Reply
AllDayTrends
AllDayTrends Mar. 26 at 7:00 PM
POWER HOUR LARGE CAP TOP STOCKS $NFLX $ABBV $LIN $CVX
0 · Reply
Guntz
Guntz Mar. 26 at 6:34 PM
$ABBV I'll take this move and hope we don't fade but wish it had been on higher volume.
0 · Reply
middleman
middleman Mar. 26 at 6:32 PM
$ABBV oh yeah!! We bounced off the 204 nicely 🙏
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 6:22 PM
$ABBV up 2% today - or $7.3B - or 9 times the Value of all of $SLS.
1 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 6:14 PM
$SLS Last Time: Does Everyone Understand, Aza+VEN, BAT - the Best Available Treatment for Control Arm Patients recently FAILED 3 Large Phase 3 Trials, conducted by $ABBV - including Failing 2 for AML Remission Maintenance. - its also Failing the REGAL P3 AML CR2 AML Remission Patients.
0 · Reply
AllDayTrends
AllDayTrends Mar. 26 at 6:09 PM
TOP BULL TRENDING LARGE CAPS GOING INTO AFTERNOON $NFLX $ABBV $LIN $CVW
0 · Reply
JulieTanzosch997
JulieTanzosch997 Mar. 26 at 5:51 PM
$ABBV steady pharma, just observing.
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 4:31 PM
$SLS $MRK the $IMGN $ABBV - $10.1B Buyout for Elahere is a $10.1B Comp for GPS - $10B Just for Platinum Resistant Ovarian Cancer. - Elahere achieved a MOS of 16.46 Months, with Some Severe Side Effects, actually Blinds Patients. Gps + Key MOS of 18.4 Months is better, with Zero Additional Toxicity. - $TERN $6.7B Buyout is a Direct Comp just for SLS009 - Phase 2B Data Presented at ASH Dec 2025 for AML High-Risk TP53/ASXL1+ ... SLS Shares Sub $40 represents the Investment Opportunity of a Lifetime. ALL Gps needs for Fda Approval, per the Pre Approved SAP, is a HR of .636 and its a done deal.
0 · Reply
Guntz
Guntz Mar. 26 at 3:10 PM
$ABBV Let's break that $210 wall
0 · Reply
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 26 at 3:08 PM
$SLS while we are seeing Miraculous ALL Pooled Survival Data in the REGAL Phase 3 Trial - Keep in mind, Gps has proven Successful to prevent relapse and extend survival in every previous trial - with Increased OS correlated with Immune Response. - Including 2 Phase 2 AML Remission Maintenance Trials. and the Best Available Treatment, BAT for Control Arm Patients Recently FAILED 3 Large Phase 3 Trials, conducted by $ABBV - including FAILING 2 AML REMISSION MAINTENANCE TRIALS - VIALE-M & VIALE-T FAILED due to toxicity.
0 · Reply
GrapeGatsby
GrapeGatsby Mar. 26 at 2:12 PM
$ABBV I like the structure here if we can get a close above 210 that would be great.
1 · Reply
Guntz
Guntz Mar. 26 at 1:03 PM
$ABBV Let's get a nice rotation into this today please. People need their meds no matter what
0 · Reply
peloswing
peloswing Mar. 26 at 12:33 PM
$ABBV Third Time's a Charm? - Successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, which once generated more than 50% of its total revenues. - 2026, $ABBV expects combined Skyrizi and Rinvoq sales of more than $31 billion, which is $0.5 billion more than its 2027 long-term guidance of $31 billion. - AbbVie has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline that should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, and also inking some early-stage deals in oncology and neuroscience areas
0 · Reply